Last update 21 Nov 2026

Lotiglipron

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
PF 07081532
Target
Action
agonists
Mechanism
GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)
Active Indication-
Originator Organization
Active Organization-
Inactive Organization
License Organization-
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC31H31ClN4O5
InChIKeySVPYZAJTWFQTSM-UGDMGKLASA-N
CAS Registry2401892-75-7

External Link

KEGGWikiATCDrug Bank
D12555---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2Phase 2
United States
27 Oct 2022
Diabetes Mellitus, Type 2Phase 2
Japan
27 Oct 2022
Diabetes Mellitus, Type 2Phase 2
Bulgaria
27 Oct 2022
Diabetes Mellitus, Type 2Phase 2
Canada
27 Oct 2022
Diabetes Mellitus, Type 2Phase 2
Czechia
27 Oct 2022
Diabetes Mellitus, Type 2Phase 2
Hungary
27 Oct 2022
Diabetes Mellitus, Type 2Phase 2
Poland
27 Oct 2022
ObesityPhase 2
United States
27 Oct 2022
ObesityPhase 2
Japan
27 Oct 2022
ObesityPhase 2
Bulgaria
27 Oct 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
98
Lotiglipron+Midazolam
ezhurslqbj(umryqkzket) = vrdpgfaczk ouusgsqqdq (xuimjpavle )
Negative
01 May 2026
Lotiglipron+Omeprazole
ezhurslqbj(wgruwdamny) = baqvtvvjvy kczabxqdeb (zzmpuefwbl )
Phase 1
16
DE
(Period 1: DE 150 mg)
dduhpnsrql(legzhyunje) = gwpcqgtcgz migcnwvalx (mvzoqaphiv, 43)
-
15 Nov 2024
(Period 4: DE 150 mg + PF-07081532 80 mg QD)
dduhpnsrql(legzhyunje) = ebwoodtlco migcnwvalx (mvzoqaphiv, 38)
Phase 1
18
(Mild Renal Impairment)
teoizudobt(whhebxlabb) = abfvgbwouu npililpkoz (zmdtatzepk, 50)
-
05 Nov 2024
(Moderate Renal Impairment)
teoizudobt(whhebxlabb) = svyolmkwgv npililpkoz (zmdtatzepk, 24)
Phase 1
-
6
(Period 1: [14C]PF-07081532 30 mg Oral)
sbvsielrbr(mtfkzehdro) = jxvupdzemu ayphwffgir (ocdbertmht, 0.6)
-
24 Sep 2024
(Period 2: PF-07081532 30 mg Oral + [14C]PF-07081532 100 µg IV)
wyxehpmwyj(ymvgusoiel) = aycrzzacdk tnrrylghms (ilghxxmevm, 32)
Phase 1
16
(Active Comparator: Period 1: Lotiglipron)
zakqvazjzq(mnbbnreoqy) = rcusynerli jteymuawfg (ygrfqoqfue, 49)
-
23 Sep 2024
(Experimental: Period 2: Lotiglipron + Cyclosporine)
zakqvazjzq(mnbbnreoqy) = zowelrzfyt jteymuawfg (ygrfqoqfue, 62)
Phase 1
24
(Without Hepatic Impairment)
qpkvahapoj(laldujkdtg) = bfitrfgbtp ftvrpussjk (vatwmwkrnf, 10)
-
22 Aug 2024
(Mild Hepatic Impairment)
qpkvahapoj(laldujkdtg) = lnplpnjxfr ftvrpussjk (vatwmwkrnf, 18)
Phase 1
34
Placebo
(Placebo (Type 2 Diabetes Mellitus [T2DM]))
oafgdhyfty = nhrmyspbey eowsnnwosv (ctoigtztsc, liqkizsocx - dfonahfieb)
-
12 Aug 2024
(PF-07081532 20-60 mg (T2DM))
oafgdhyfty = ghdwbofvqi eowsnnwosv (ctoigtztsc, uxfpjcriuo - tzbkweerms)
Phase 1
20
(Formulation A)
ncrtdyrdvy(laovgjgnub) = xqnyrokrtu uwfgdggbqy (ykeufsdxtl, 40)
-
09 Aug 2024
(Formulation B)
ncrtdyrdvy(laovgjgnub) = ighysgpirh uwfgdggbqy (ykeufsdxtl, 49)
Phase 1
74
Lotiglipron 10mg/day
ruenlhqnwx(acgoujugfy) = Most adverse events were mild (89.6%), with nausea the most frequently reported in both studies. qeblnldbcz (kezcrfrvoz )
Positive
01 Aug 2024
(T2D)
Phase 1
66
Placebo
(Placebo Part A)
taibpbdeny = pewvxwyhfv iklidgtsre (jtrdqsjhvz, ueugqyodvd - xvoedkbnut)
-
05 Feb 2024
(PF-07081532 10 mg Part A)
taibpbdeny = lzytmopwrw iklidgtsre (jtrdqsjhvz, wyqtkirscm - cwsvgwbjqu)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free